These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7629847)

  • 1. Economics of hypertension control.
    Fletcher A
    J Med Liban; 1994; 42(3):138-44. PubMed ID: 7629847
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacoeconomics of hypertension control: basic principles of economic evaluation.
    Wilson TW; Chockalingam A; Quest DW
    J Hum Hypertens; 1996 Feb; 10 Suppl 2():S19-22. PubMed ID: 8868039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The pharmaco-economics of the treatment of arterial hypertension: data and controversies].
    Rorive G; Delporte JP
    Bull Mem Acad R Med Belg; 1998; 153(7-9):317-21; discussion 322-4. PubMed ID: 10100395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The comparative assessment of the efficacy of hypotensive preparations in stage-II hypertension].
    Tiurin VP; Fursov AN; Gospodarenko AL; Liapkova NB; Orlov FA
    Voen Med Zh; 1997 Nov; 318(11):46-7. PubMed ID: 9461836
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost of hypertension medications: is it a barrier to hypertension control?
    Roccella EJ
    Geriatrics; 1989 Oct; 44 Suppl B():49-55. PubMed ID: 2680780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PANDORA project: results of the cost of illness analysis.
    Degli Esposti E; Berto P; Ruffo P; Buda S; Degli Esposti L; Sturani A;
    J Hum Hypertens; 2001 May; 15(5):329-34. PubMed ID: 11378835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Medical cost of cardiovascular risk factors prevention in France].
    Marques-Vidal P; Bongard V; Arveiler D; Amouyel P; Ducimetière P; Ferrières J
    Arch Mal Coeur Vaiss; 2002 Apr; 95(4):275-81. PubMed ID: 12055766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost of treating high blood pressure in general practice in France.
    Tibi-Levy Y; de Pouvourville G; Westerloppe J; Bamberger M
    Eur J Health Econ; 2008 Aug; 9(3):229-36. PubMed ID: 17566802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost analysis of different pharmacological treatment strategies in elderly hypertensives.
    Linjer E; Hedner T; Jönsson B; Ekbom T; Lindholm LH; Dahlöf B; de Faire U; Scherstén B;
    Blood Press; 2005; 14(2):107-13. PubMed ID: 16036488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Uncontrolled arterial hypertension: pharmaco-economic interest of hospital diagnostic work-up].
    Ragot S; Sosner P; Herpin D
    Arch Mal Coeur Vaiss; 2002; 95(7-8):733-7. PubMed ID: 12365089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of hypertension. Between progress and cost control].
    MMW Fortschr Med; 1999 Oct; 141(42):46. PubMed ID: 10912105
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of hypertension in Sweden: treatment of patients with hypertension costs more than a billion crowns per year].
    Johannesson M; Borgqvist L; Jönsson B; Råstam L
    Lakartidningen; 1991 Mar; 88(12):1103-6. PubMed ID: 2016946
    [No Abstract]   [Full Text] [Related]  

  • 13. A retrospective analysis comparing the costs and cost effectiveness of amlodipine and enalapril in the treatment of hypertension.
    Doyle J; Omvik P; Arikian S; Casciano J; Casciano R; Gonzalez MA; Arocho R
    Manag Care Interface; 2001 Mar; 14(3):82-7. PubMed ID: 11301961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost containment and the treatment of hypertension.
    Chillag SA
    J S C Med Assoc; 1985 Feb; 81(2):61-4. PubMed ID: 3856703
    [No Abstract]   [Full Text] [Related]  

  • 15. [Medical economics of antihypertensive agents].
    Yamazaki T
    Nihon Rinsho; 2006 Aug; 64 Suppl 6():285-8. PubMed ID: 16981557
    [No Abstract]   [Full Text] [Related]  

  • 16. The cost-effectiveness of hypertension treatment in Sweden: an analysis of the criteria for intervention and the choice of drug treatment.
    Johannesson M
    J Hum Hypertens; 1996 Feb; 10 Suppl 2():S23-6. PubMed ID: 8868040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacoeconomic aspects of the treatment of essential hypertension].
    Martynov AI; Giliarevskiĭ SR; Ostroumova OD; Nesterova MV; Mamaev VI
    Ter Arkh; 2001; 73(9):82-8. PubMed ID: 11642090
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-benefit of treating hypertension.
    Jönsson BG
    J Hypertens Suppl; 1994 Dec; 12(10):S65-70. PubMed ID: 7769494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-minimization analysis of initial antihypertensive therapy in patients with mild-to-moderate essential diastolic hypertension.
    Hilleman DE; Mohiuddin SM; Lucas BD; Stading JA; Stoysich AM; Ryschon K
    Clin Ther; 1994; 16(1):88-102; discussion 87. PubMed ID: 7911403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical importance of direct hospital costs in patients with arterial hypertension in a university hospital, Rio de Janeiro, Brazil].
    de Souza e Silva NA; Aguiar GR; Nogueira Ada R; Duarte MM; Alves RH
    Rev Saude Publica; 1986 Aug; 20(4):293-302. PubMed ID: 3576101
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.